Target
GPC3
2 abstracts
Abstract
Phase I study of C-CAR031, a GPC3-specific TGFβRIIDN armored autologous CAR-T, in patients with advanced hepatocellular carcinoma (HCC).Org: AbelZeta Pharma, Inc., Shanghai, China, AstraZeneca, Cambridge, United Kingdom,
Abstract
Novel peptide binder to Glypican-3 for targeted radiopharmaceutical therapy of hepatocellular carcinoma.Org: RayzeBio, PeptiDream,